Silent maternal autoimmunity unmasked by neonatal atrioventricular block: a case of neonatal lupus
DOI:
https://doi.org/10.18203/2349-3291.ijcp20261154Keywords:
Neonatal lupus, Atrioventricular block, Autoimmune disease, BradycardiaAbstract
Neonatal lupus erythematosus (NLE) is a rare autoimmune condition resulting from transplacental transfer of maternal autoantibodies, most commonly anti-Ro/SSA and anti-La/SSB, and may present with cardiac, cutaneous, or hematological manifestations. We report a late preterm male neonate who presented on day one of life with respiratory distress and persistent bradycardia. Electrocardiogram revealed atrioventricular block with 2:1 conduction, while echocardiography showed no structural cardiac abnormalities. Autoimmune evaluation demonstrated elevated antinuclear antibodies, anti-Ro, anti-La, and anti-dsDNA antibodies, confirming the diagnosis of neonatal lupus. The neonate was managed with isoprenaline infusion followed by oral beta-blocker therapy, resulting in stabilization of heart rate. In view of these findings, the asymptomatic mother was evaluated and found to have elevated ANA, anti-Ro, and anti-La antibodies, suggestive of subclinical systemic lupus erythematosus. The infant remained clinically stable on follow-up, with appropriate neurodevelopment and later development of hypopigmented skin lesions, and is planned for pacemaker insertion at a later stage. This case highlights the importance of considering neonatal lupus in cases of unexplained neonatal bradycardia and emphasizes the need for evaluation of maternal autoimmune status even in the absence of symptoms.
References
Diaz-Frias J, Pal A. Neonatal Lupus Erythematosus. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2026.
Lee LA. Neonatal lupus: clinical features and management. Paediatr Drugs. 2004;6(2):71-8.
Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011;124(18):1927-35.
Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol. 2011;40(1):27-41.
Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008;117(4):485-93.
Jaeggi ET, Silverman ED, Laskin C, Kingdom J, Golding F, Weber R. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol. 2011;57(13):1487-92.
Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol. 2001;37(1):238-42.
Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, Huong DL, Denjoy I, Vauthier D, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum. 2004;50(10):3187-94.
Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76-82.
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020;76(3):292-302.